Stocktoria
Syndax Pharmaceuticals Inc SNDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-03-03
Syndax Pharmaceuticals Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $0 | $139.7M |
| R&D expense | $258.8M | $241.6M | $163.0M | $118.5M | $88.2M |
| SG&A expense | $179.7M | $120.9M | $66.9M | $33.3M | $25.2M |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M |
| Interest expense | — | — | $208,000 | $3.1M | $1.9M |
| Income tax | $433,000 | — | — | — | $0 |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M |
| EPS (diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 |
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M |
| Free cash flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M | $29.0M |
| Cash & equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $222.0M |
| Inventory | $32.8M | $366,000 | $0 | — | — |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M |
| Shareholders' equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M |
Source: SEC EDGAR filings · CIK 0001395937 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.